From OHC, Specialists in the Treatment of Adult Cancers and Blood Disorders

November 6, 2019

OHC’s David M. Waterhouse, MD, MPH, is leading a national clinical trial as the principal investigator to evaluate a new treatment option for patients whose advanced non-small cell lung cancer has not responded to chemotherapy or immunotherapy treatments.

“Cancer is a very individualized disease in that one person’s cancer isn’t the same as another person’s cancer,” said Dr. Waterhouse, OHC medical oncologist, hematologist, and co-director of research. “In terms of treatment, this means one size does not fit all. One treatment doesn’t work for everyone. So, OHC is continuously working to help develop new therapies so we can offer more patients more treatment options.”

This new clinical trial at OHC for lung cancer patients is evaluating the combination of the drug, Sitravatinib, which binds to an enzyme and works to destroy cancer, with Nivolumab, an immunotherapy drug that helps your immune system cells attack cancer cells. This combination is being tested against the use of the chemotherapy drug, Docetaxel.

“This is like a two-pronged assault. On one hand, we have a drug that will attack the cancer directly. On the other hand, we have a drug that helps your immune system attack the cancer,” explained Dr. Waterhouse. “We’ve had success with this approach with other cancers, and now we may have similar results with lung cancer. We want to be able to tell these patients there’s still hope for their condition.”

OHC chose to participate in this trial because of the potential impact it can have on people fighting non-small cell lung cancer – not only those who live here in this region, but for people worldwide.

“It’s an incredible feeling when you’ve helped discover a successful treatment for cancer because we’re helping patients here in our community and people we don’t even know who live on the other side of the world.” Dr. Waterhouse added. “And OHC continues to push forward until we have a treatment for every individual type of cancer.”

OHC is the only adult cancer group in the region participating in this study, and one of only two in Ohio. You can learn more about this and other clinical trials here or call OHC at 1-800-710-4674 to request an appointment with an OHC cancer expert or for a second opinion.

Pictured above is Dr. David Waterhouse, MD, MPH, presenting at an earlier ASCO conference.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *